κΉνν
2018-07-17T00:59:32Z
2018-07-17T00:59:32Z
2016-06
ANNALS OF THE RHEUMATIC DISEASES, v. 75, NO 6, Page. 1016-1023
0003-4967
1468-2060
https://ard.bmj.com/content/75/6/1016
https://repository.hanyang.ac.kr/handle/20.500.11754/72606
Background Increased risk of some comorbidities has been reported in spondyloarthritis (SpA). Recommendations for detection/management of some of these comorbidities have been proposed, and it is known that a gap exists between these and their implementation in practice.
Objective To evaluate (1) the prevalence of comorbidities and risk factors in different countries worldwide, (2) the gap between available recommendations and daily practice for management of these comorbidities and (3) the prevalence of previously unknown risk factors detected as a result of the present initiative.
Methods Cross-sectional international study with 22 participating countries (from four continents), including 3984 patients with SpA according to the rheumatologist.
Statistical analysis The prevalence of comorbidities (cardiovascular, infection, cancer, osteoporosis and gastrointestinal) and risk factors; percentage of patients optimally monitored for comorbidities according to available recommendations and percentage of patients for whom a risk factor was detected due to this study.
Results The most frequent comorbidities were osteoporosis (13%) and gastroduodenal ulcer (11%). The most frequent risk factors were hypertension (34%), smoking (29%) and hypercholesterolaemia (27%). Substantial intercountry variability was observed for screening of comorbidities (eg, for LDL cholesterol measurement: from 8% (Taiwan) to 98% (Germany)). Systematic evaluation (eg, blood pressure (BP), cholesterol) during this study unveiled previously unknown risk factors (eg, elevated BP (14%)), emphasising the suboptimal monitoring of comorbidities.
Conclusions A high prevalence of comorbidities in SpA has been shown. Rigorous application of systematic evaluation of comorbidities may permit earlier detection, which may ultimately result in an improved outcome of patients with SpA.
This study was conducted with the financial support of Abbvie, Pfizer and UCB, who provided an unrestricted grant. The funders did not have any role in the design and conduct of the study; collection, management, analysis and interpretation of the data; preparation, review or approval of the manuscript and decision to submit the manuscript for publication.
en
BMJ PUBLISHING GROUP
OF-THE-LITERATURE
POPULATION-BASED COHORT
BONE-MINERAL DENSITY
ANKYLOSING-SPONDYLITIS
RHEUMATOID-ARTHRITIS
BODY-COMPOSITION
CANCER INCIDENCE
HEART-DISEASE
RISK
RECOMMENDATIONS
Prevalence of comorbidities and evaluation of their screening in spondyloarthritis: results of the international cross-sectional ASAS-COMOSPA study
Article
6
75
10.1136/annrheumdis-2015-208174
1016-1023
ANNALS OF THE RHEUMATIC DISEASES
Molto, Anna
Etcheto, Adrien
van der Heijde, Desiree
Landewe, Robert
van den Bosch, Filip
Bautista Molano, Wilson
Burgos-Vargas, Ruben
Cheung, Peter P.
Collantes-Estevez, Eduardo
Kim, Tae-Hwan
2016001377
S
COLLEGE OF MEDICINE[S]
DEPARTMENT OF MEDICINE
thkim